SUPN:NSD-Supernus Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 19.70

Change

-0.39 (-1.94)%

Market Cap

USD 1.06B

Volume

0.31M

Average Target Price

USD 26.67 (+35.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

-0.64 (-4.08%)

USD8.11B 29.43 7.35
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
PCRX Pacira BioSciences, Inc

-1.65 (-2.97%)

USD2.37B 870.20 69.93
CRON Cronos Group Inc

-0.30 (-5.15%)

USD2.03B 2.89 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.07 (-0.73%)

USD1.54B 15.31 12.76
ENDP Endo International plc

-0.24 (-4.15%)

USD1.33B N/A 8.81
APHA Aphria Inc

+0.02 (+0.44%)

USD1.31B 57.50 454.68
ATNX Athenex, Inc

+0.23 (+2.01%)

USD1.07B N/A N/A
AMPH Amphastar Pharmaceuticals, Inc

-0.55 (-2.64%)

USD0.99B 260.50 31.99
TLRY Tilray, Inc

-0.87 (-12.93%)

USD0.90B N/A N/A

ETFs Containing SUPN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.95% 66% D 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.95% 66% D 36% F
Trailing 12 Months  
Capital Gain -29.99% 48% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.99% 48% F 20% F
Trailing 5 Years  
Capital Gain 16.50% 81% B- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.50% 81% B- 50% F
Average Annual (5 Year Horizon)  
Capital Gain 20.83% N/A N/A 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.83% N/A N/A 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 55.17% N/A N/A 20% F
Risk Adjusted Return 37.76% N/A N/A 60% D-
Market Capitalization 1.06B 88% B+ 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.15 73% C 75% C
Price/Book Ratio 1.59 74% C 61% D-
Price / Cash Flow Ratio 7.39 25% F 39% F
EV/EBITDA 5.82 81% B- 81% B-
Management Effectiveness  
Return on Equity 19.88% 96% A 91% A-
Return on Invested Capital 13.25% 91% A- 85% B
Return on Assets 7.84% 97% A+ 93% A
Debt to Equity Ratio 57.97% 39% F 39% F
Technical Ratios  
Short Ratio 11.87 25% F 7% F
Short Percent 14.73% 31% F 15% F
Beta 1.39 47% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.